$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000106282213000023 Filed on May 10, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$214.0K	$360.0K	$300.0K
YoY Change	7.54%	20.0%	-49.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.700M	$4.300M	$5.600M
YoY Change	-7.84%	-23.21%	0.0%
% of Gross Profit
Research & Development	$23.69M	$20.33M	$23.04M
YoY Change	22.41%	-11.76%	-3.7%
% of Gross Profit
Depreciation & Amortization	$800.0K	$793.0K	$1.125M
YoY Change	-27.27%	-29.51%	-13.93%
% of Gross Profit
Operating Expenses	$28.84M	$25.92M	$29.68M
YoY Change	12.3%	-12.69%	-0.16%
Operating Profit	-$28.62M	-$25.56M	-$29.38M
YoY Change	12.34%	-13.03%	0.85%
Interest Expense	$496.0K	$506.0K	$537.0K
YoY Change	-6.42%	-5.77%	-11.53%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$34.00K	-$4.000K
YoY Change	-119.05%	-950.0%	-114.81%
Pretax Income	-$29.10M	-$26.00M	-$29.90M
YoY Change	12.36%	-13.04%	1.01%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.08M	-$25.97M	-$29.87M
YoY Change	12.14%	-13.04%	0.81%
Net Earnings / Revenue	-13588.79%	-7215.0%	-9956.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$397.0K	-$355.2K	-$435.9K
COMMON SHARES
Basic Shares Outstanding	513.0M shares	513.0M shares	480.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.9M	$196.7M	$253.2M
YoY Change	-24.32%	-22.31%	34.04%
Cash & Equivalents	$23.25M	$34.25M	$29.01M
Short-Term Investments	$151.7M	$162.5M	$224.2M
Other Short-Term Assets	$6.684M	$8.438M	$5.143M
YoY Change	1.55%	64.07%	51.26%
Inventory
Prepaid Expenses
Receivables	$1.014M	$863.0K	$186.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$183.1M	$206.5M	$259.0M
YoY Change	-23.17%	-20.28%	34.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.15M	$42.62M	$45.53M
YoY Change	-5.33%	-6.38%	-12.11%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$65.00K	$88.00K	$181.0K
YoY Change	-58.6%	-51.38%	-39.67%
Total Long-Term Assets	$140.3M	$140.8M	$143.8M
YoY Change	-1.73%	-2.08%	-4.26%
TOTAL ASSETS
Total Short-Term Assets	$183.1M	$206.5M	$259.0M
Total Long-Term Assets	$140.3M	$140.8M	$143.8M
Total Assets	$323.4M	$347.3M	$402.8M
YoY Change	-15.13%	-13.78%	17.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.281M	$5.442M	$5.324M
YoY Change	37.17%	2.22%	-3.2%
Accrued Expenses	$11.32M	$9.704M	$13.71M
YoY Change	-24.75%	-29.22%	78.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$22.68M	$1.607M	$1.478M
YoY Change	1401.85%	8.73%	23.17%
Total Short-Term Liabilities	$40.90M	$17.38M	$20.93M
YoY Change	89.76%	-16.97%	44.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$21.46M	$23.06M
YoY Change	-100.0%	-6.96%	-14.58%
Other Long-Term Liabilities	$35.26M	$34.08M	$57.17M
YoY Change	-40.52%	-40.39%	-10.39%
Total Long-Term Liabilities	$35.26M	$55.54M	$80.23M
YoY Change	-56.98%	-30.78%	-11.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.90M	$17.38M	$20.93M
Total Long-Term Liabilities	$35.26M	$55.54M	$80.23M
Total Liabilities	$108.3M	$105.1M	$133.8M
YoY Change	-20.46%	-21.49%	7.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$954.9M	-$925.8M	-$819.5M
YoY Change	12.95%	12.97%
Common Stock	$514.0K	$514.0K	$481.0K
YoY Change	6.86%	6.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.503M	$1.503M	$630.0K
YoY Change	138.57%	138.57%
Treasury Stock Shares	814.0K shares	814.0K shares	380.0K shares
Shareholders Equity	$215.1M	$242.2M	$269.0M
YoY Change
Total Liabilities & Shareholders Equity	$323.4M	$347.3M	$402.8M
YoY Change	-15.13%	-13.78%	17.3%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$29.08M	-$25.97M	-$29.87M
YoY Change	12.14%	-13.04%	0.81%
Depreciation, Depletion And Amortization	$800.0K	$793.0K	$1.125M
YoY Change	-27.27%	-29.51%	-13.93%
Cash From Operating Activities	-$21.10M	-$24.27M	-$27.00M
YoY Change	-4.09%	-10.11%	25.36%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	$839.0K	$234.0K
YoY Change	300.0%	258.55%	-53.85%
Acquisitions
YoY Change
Other Investing Activities	$10.90M	$29.90M	-$129.3M
YoY Change	-59.48%	-123.12%	2593.75%
Cash From Investing Activities	$10.40M	$29.11M	-$129.6M
YoY Change	-61.34%	-122.46%	2336.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$624.0K	$233.0K
YoY Change		167.81%	-548.08%
Debt Paid & Issued, Net		$387.0K	$353.0K
YoY Change		9.63%	24.3%
Cash From Financing Activities	-300.0K	-$1.011M	-$722.0K
YoY Change	50.0%	40.03%	211.21%
NET CHANGE
Cash From Operating Activities	-21.10M	-$24.27M	-$27.00M
Cash From Investing Activities	10.40M	$29.11M	-$129.6M
Cash From Financing Activities	-300.0K	-$1.011M	-$722.0K
Net Change In Cash	-11.00M	$3.825M	-$157.3M
YoY Change	-334.04%	-102.43%	480.65%
FREE CASH FLOW
Cash From Operating Activities	-$21.10M	-$24.27M	-$27.00M
Capital Expenditures	-$400.0K	$839.0K	$234.0K
Free Cash Flow	-$20.70M	-$25.11M	-$27.24M
YoY Change	-5.48%	-7.81%	23.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7661000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5442000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1378000	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	863000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8922000	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9704000	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80882000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83416000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	42000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1168961000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1166605000	USD
CY2012Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1718000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2109000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2100000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q1	us-gaap	Assets Assets	347275000	USD
CY2012Q4	us-gaap	Assets Assets	371778000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	230935000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	206464000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34248000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29010000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3825000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-157299000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	512000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25955000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29946000	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	152000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	284000	USD
CY2013Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	128000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	628000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13910000	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2013Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1125000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	793000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1264000	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2081000	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31184000	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	57114000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	55033000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4324000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4565000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	5300000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	851000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	905000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-515000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-164000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	24000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	21000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2089000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1395000	USD
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	506000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	537000	USD
CY2013Q1	us-gaap	Interest Paid Net InterestPaidNet	480000	USD
CY2012Q1	us-gaap	Interest Paid Net InterestPaidNet	516000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	53000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	56000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	105100000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	105067000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	371778000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	347275000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18285000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17381000	USD
CY2012Q1	us-gaap	Licenses Revenue LicensesRevenue	148000	USD
CY2013Q1	us-gaap	Licenses Revenue LicensesRevenue	76000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1574000	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1607000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21877000	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21457000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1011000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-722000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-129575000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29107000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24271000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27002000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-29868000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-25974000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	25915000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	29683000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29383000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25555000	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	8438000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6349000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	88000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	839000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-78000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32283000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34079000	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
CY2012Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	285000	USD
CY2013Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
CY2012Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	151776000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	234000	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52000	USD
CY2012Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-136000	USD
CY2013Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2012Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22435000	USD
CY2013Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	110843000	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	57000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42623000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42634000	USD
CY2012Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2013Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2012Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	353000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	387000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23037000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20327000	USD
CY2012Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q1	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-925806000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-899832000	USD
CY2013Q1	us-gaap	Revenues Revenues	360000	USD
CY2012Q1	us-gaap	Revenues Revenues	300000	USD
CY2013Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1264000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2013Q1	us-gaap	Secured Debt SecuredDebt	23100000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1718000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2109000	USD
CY2013Q1	us-gaap	Short Term Investments ShortTermInvestments	162915000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	192785000	USD
CY2012Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	52000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	242208000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	266678000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2012Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	268971000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	242208000	USD
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	380000	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	630000	USD
CY2012Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	285000	USD
CY2013Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	19000	USD
CY2012Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-78000	USD
CY2012Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2081000	USD
CY2012Q1	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	480324000	shares
CY2013Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	779000	USD
CY2012Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	681000	USD
CY2012Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1037000	USD
CY2013Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1330000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
CY2013Q1	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	512428000	shares
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	513025272	shares
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-13-000023-index-headers.html	Edgar Link	pending
0001062822-13-000023-index.html	Edgar Link	pending
0001062822-13-000023.txt	Edgar Link	pending
0001062822-13-000023-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
lxrx-20130331.xml	Edgar Link	completed
lxrx-20130331.xsd	Edgar Link	pending
lxrx-20130331_cal.xml	Edgar Link	unprocessable
lxrx-20130331_def.xml	Edgar Link	unprocessable
lxrx-20130331_lab.xml	Edgar Link	unprocessable
lxrx-20130331_pre.xml	Edgar Link	unprocessable
lxrx331201310-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q2 Form 10-Q Financial Statement

#000106282213000023 Filed on May 10, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q2 Form 10-Q Financial Statement

#000106282213000023 Filed on May 10, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx